New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2014
05:49 EDTBSXBoston Scientific presents data on Precision Spectra SCS
New retrospective data highlighting the Boston Scientific Precision Spectra Spinal Cord Stimulator, or SCS, System demonstrate the device provided sustained and highly significant relief of low-back pain six months after implantation. The retrospective study of 213 patients at 13 centers is focused on patients with chronic pain who were treated with the Precision Spectra SCS System. To date, 140 patients have reached six months post-implant. Results include: Sustained and highly significant reduction in pain from an average baseline score of 7.15, on a 10-point scale, to an average score of 2.93 at six months post-implant. In those patients with only low-back pain, sustained and highly significant reduction of low back pain, from an average baseline score of 7.53, on a 10-point scale, to an average of 3.45 at six months post-implant. In those patients with severe low back pain, sustained and highly significant reduction in pain, from an average score of 8.78 at baseline to 3.68 at 6 months post-implant.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:31 EDTBSXBoston Scientific should be bought on weakness, says RBC Capital
Subscribe for More Information
November 19, 2014
12:11 EDTBSXBoston Scientific says Synergy stent met primary endpoint in trial
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific SYNERGY Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure. Additionally, favorable rates for key secondary endpoints were observed with the SYNERGY Stent. Dean Kereiakes, M.D., F.A.C.C., F.S.C.A.I., the principal investigator for the EVOLVE II Trial, presented the study results today in a Late Breaking Clinical Trial session at the American Heart Association Scientific Session 2014 in Chicago. Key findings for the SYNERGY Stent from the EVOLVE II Trial include the following: At 12 months, the TLF rate was 6.4% per protocol and 6.7% for intent-to-treat. Stent Thrombosis was rare, with Definite or Probable ST occurring in only 0.4% of patients through one year. No Definite ST occurred after 24 hours.
06:30 EDTBSXJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 18, 2014
11:35 EDTBSXBoston Scientific November volatility elevated into investor day
Subscribe for More Information
07:37 EDTBSXStifel to hold a conference
Subscribe for More Information
06:08 EDTBSXBoston Scientific to host investor meeting
Investor meeting to be held on November 19 at 2 pm. Webcast Link
November 17, 2014
09:08 EDTBSXBoston Scientific announces first U.S. procedures with Symphion completed
Subscribe for More Information
November 14, 2014
12:53 EDTBSXOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
November 13, 2014
17:10 EDTBSXBoston Scientific S-ICD System receives favorable coding, payment designations
Subscribe for More Information
November 12, 2014
07:27 EDTBSXNorth American Spine Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use